Today: 29 June 2026
Ondas Stock Saw Fast Moves; Monday Still Ahead
17 May 2026
2 mins read

Ondas Stock Saw Fast Moves; Monday Still Ahead

New York, May 17, 2026, 09:02 EDT

  • Ondas ended Friday at $10.62, falling 5.26%. That followed a 26.52% gain Thursday. The stock stayed roughly 17% above where it finished on May 8.
  • Ondas Inc. lifted its 2026 revenue target to $390 million or more after reporting first-quarter revenue of $50.1 million.
  • The May 15 prospectus covered the resale of 3,342,378 shares linked to the World View deal. Proceeds go to selling stockholders, not Ondas.

Ondas Inc. is starting the week with heavy trading after a record quarter sparked a jump in the stock, followed by a pullback as sellers stepped in.

Nasdaq’s main session is Monday to Friday, 9:30 a.m. to 4 p.m. Eastern, and it’s closed on Sunday. Monday’s opening will be the first real look at whether the earnings jump can stick following Friday’s drop.

Why it matters now: Ondas is trading as a play on autonomous drones, defense robotics, and counter-UAS tech—systems for tracking or stopping drones. First-quarter revenue jumped more than ten times versus last year and climbed 66% over Q4, as the autonomous systems segment drove growth, the company said.

Ondas told investors in its May 14 report it now has a pro forma backlog of $457 million, a jump from $68.3 million at the end of 2025. The company also raised its 2026 revenue target, now expecting at least $390 million for the year.

Ondas CEO Eric Brock said the company has “strong visibility into our 2026 targets” and is seeing demand in counter-drone and defense robotics. Oshri Lugassy, co-CEO at Ondas Autonomous Systems, said they are delivering “combat-proven, multi-layered solutions” for defense and security. Ondas Inc.

Sharp moves in Ondas. Shares jumped 26.52% Thursday to $11.21 and then slipped 5.26% Friday, closing at $10.62. Friday volume topped 138 million shares after Thursday saw almost 245 million trade.

Defense-tech names moved around on Thursday as AeroVironment added 2.7% and Karman Holdings lost 1.9%. The iShares U.S. Aerospace & Defense ETF gave up 0.6%. Ondas’ strategic partner Palantir was up 2.8%. Barron’s covered the moves. The rally in Ondas stood out in the busy sector.

Quarterly filings from Ondas hit on May 15, with the company also registering resale shares tied to some World View sellers. It’s a typical step after a deal but can hang over the share price if there’s a lot more stock ready to hit the market.

But the risk is straightforward. Ondas posted an operating loss of $42.7 million and an adjusted EBITDA loss of $10.9 million. Net income was lifted by a $389.5 million non-cash gain from warrant accounting. Adjusted EBITDA, which excludes interest, taxes, depreciation, amortization and some other items, is a non-GAAP figure; Ondas said itself that these measures are supplemental and not a replacement for GAAP numbers.

Neil Laird, chief financial officer, told investors the warrant gain was “purely accounting driven” and said reported earnings could keep fluctuating because of that. Brock told analysts it’s “hard to be precise” about turning a large backlog into quarterly revenue. Investing.com

Traders are watching if the stock can hold above Friday’s close, if defense-tech stocks keep falling, and how the resale filing affects sentiment for a company already busy with acquisitions. Ondas’s next investor event is its annual meeting May 28 in West Palm Beach, Florida.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • AbbVie Stock Surges, Boosting Valuation of $10.9 Billion Apogee Acquisition
    June 28, 2026, 6:38 PM EDT. AbbVie Inc. shares climbed 4.2% to a 52-week high of $253.35 on June 26, lifting the company's market value by approximately $65 billion since June 18. This surge is nearly six times the $10.9 billion cash price AbbVie is paying for Apogee Therapeutics. The acquisition, financed through debt, includes Apogee's late-stage IL-13 antibody zumilokibart for atopic dermatitis. Despite a 49% premium paid over Apogee's June 18 close, AbbVie expects a reduced adjusted earnings per share (EPS) in 2026 and 2027, with accretion only anticipated by 2032. Investors appear focused on AbbVie's long-term immunology growth, with key drugs Skyrizi and Rinvoq generating $6.6 billion in Q1 revenue. AbbVie's CEO described the deal as creating significant long-term shareholder value.

Latest articles

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
Kroger (NYSE:KR) chicken alert puts Private Selection label controls in focus

Kroger (NYSE:KR) chicken alert puts Private Selection label controls in focus

29 June 2026
Kroger (NYSE:KR) faces scrutiny after a USDA alert flagged mislabeled Private Selection Honey Dijon chicken in nine states, but with no confirmed adverse reactions and the product already off shelves, the stock closed Friday at $57.73, down 5 cents; any expansion of affected lots or confirmed cases could alter risk for investors.
Stripe’s secondary share price brings focus back to its paused IPO
Previous Story

Stripe’s secondary share price brings focus back to its paused IPO

Tesla Stock Gets a Weekend Shock as Model Y Prices Rise After Friday Slide
Next Story

Tesla Stock Gets a Weekend Shock as Model Y Prices Rise After Friday Slide

Go toTop